Breast cancer, the most common neoplasm in women of all ages, is the leading cause of cancer-related mortality in women worldwide. Markers to help to predict the risk of progression and ultimately provide non-surgical treatment options would be of great benefit. At present, there are no available molecular markers to predict the risk of carcinoma in situ progression to invasive cancer; therefore, all women diagnosed with this type of malignancy must undergo surgery. Breast cancer is a heterogeneous complex disease, and different patients respond differently to different treatments. In breast cancer, analysis using immunohistochemical markers remains an essential component of routine pathological examinations, and plays an import role in the...
SummaryBasal-like breast cancers (BLBCs) are aggressive, and their drivers are unclear. We have foun...
The expression of ras mRNA levels in 27 human sporadic breast cancer specimens was examined, and com...
Summary. Breast cancer is the most common malignant tumor in women around the world. It is a disease...
Introduction: Ras guanine nucleotide exchange factors (RasGEFs) mediate the activation of the Ras si...
The protein product of the ras cellular oncogene(s) (p21) was assayed in primary breast carcinomas f...
BACKGROUND: Activated forms of Ras are enhanced in both breast cancer as well as the cell lines with...
Young age does not seem to be directly related to the aggressiveness of the disease among patients w...
Background An important component of the RAS signalling pathway, the RAS p21 oncogene, is frequen...
Breast cancer is the most frequently diagnosed cancer in women. Although breast cancer is mainly dia...
Oncogenic activation of RAS isoforms leads tumor initiation and progression in many types of cancers...
The expression of the ras and c-erbB2 oncoproteins (p21 and p185, respectively), together with estro...
Although Ras genes are frequently mutated in human tumors, these mutations are uncommon in breast ca...
RasGRP3 is a member of the Ras guanine nucleotide releasing protein (RasGRP) family of the Ras-speci...
The differential expression of the ras oncogene product p21 in the primary tumor, regional nodes, an...
Basal-like breast cancers (BLBCs) are aggressive, and their drivers are unclear. We have found that ...
SummaryBasal-like breast cancers (BLBCs) are aggressive, and their drivers are unclear. We have foun...
The expression of ras mRNA levels in 27 human sporadic breast cancer specimens was examined, and com...
Summary. Breast cancer is the most common malignant tumor in women around the world. It is a disease...
Introduction: Ras guanine nucleotide exchange factors (RasGEFs) mediate the activation of the Ras si...
The protein product of the ras cellular oncogene(s) (p21) was assayed in primary breast carcinomas f...
BACKGROUND: Activated forms of Ras are enhanced in both breast cancer as well as the cell lines with...
Young age does not seem to be directly related to the aggressiveness of the disease among patients w...
Background An important component of the RAS signalling pathway, the RAS p21 oncogene, is frequen...
Breast cancer is the most frequently diagnosed cancer in women. Although breast cancer is mainly dia...
Oncogenic activation of RAS isoforms leads tumor initiation and progression in many types of cancers...
The expression of the ras and c-erbB2 oncoproteins (p21 and p185, respectively), together with estro...
Although Ras genes are frequently mutated in human tumors, these mutations are uncommon in breast ca...
RasGRP3 is a member of the Ras guanine nucleotide releasing protein (RasGRP) family of the Ras-speci...
The differential expression of the ras oncogene product p21 in the primary tumor, regional nodes, an...
Basal-like breast cancers (BLBCs) are aggressive, and their drivers are unclear. We have found that ...
SummaryBasal-like breast cancers (BLBCs) are aggressive, and their drivers are unclear. We have foun...
The expression of ras mRNA levels in 27 human sporadic breast cancer specimens was examined, and com...
Summary. Breast cancer is the most common malignant tumor in women around the world. It is a disease...